UP Gov Announces INR 2500 Cr Investment to Boost Pharma Manufacturing Ecosystem

The new investment will support the development of two key infrastructure projects, including a Bulk drug and Pharma park in Lalitpur and a Medical Device park near the Noida International Airport, NCR region.

The government of Uttar Pradesh has announced plans to invest approximately INR 2,500 crore aimed at strengthening the healthcare manufacturing ecosystem with a focus on pharmaceuticals and medical devices.

The new investment will support the development of two key infrastructure projects, including a Bulk drug and Pharma park in Lalitpur and a Medical Device park near the Noida International Airport, NCR region.

As per reports, around INR 2,000 crore will be allocated to the 1,500-acre bulk drug park in Lalitpur, while approximately INR 500 crore will be invested in the 350-acre medical device park near the Noida International Airport.

The Lalitpur project is expected to offer plug-and-play infrastructure enabling pharma companies to set up operations quickly.

The project is also anticipated to generate significant employment once it gets fully operational.

Meanwhile, the medical device park in Greater Noida is being developed to support logistics and export, which is expected to strengthen India’s position in the global medical device manufacturing market.

In addition, the Yamuna Expressway Industrial Development Authority (YEIDA) has also outlined plans to develop flatted factory complexes for medical device manufacturing, which are expected to facilitate ease of operations for companies and encourage faster project execution.

These developments come amid growing investor interest in the state’s pharmaceutical sector, supported by infrastructure-led initiatives and policy backing.

Reportedly, the Yogi Government has attracted pharma investment proposals exceeding INR 38,000 crore, including around 210 proposals worth approximately INR 28,000 crore, which were received during the Uttar Pradesh Global Investors’ Summit 2023.

Further, some recent proposals in the sector also include investments from companies such as INR 1,250 crore from Arna Pharma, INR 1,250 crore from Biogenta Lifesciences, INR 737 crore from Shukra Pharmaceuticals Limited, INR 590 crore from Walter Bushnell Enterprises, and INR 553 crore from Jhanvika Labs.

The initiative aligns with the state’s broader goal of boosting domestic production of critical drugs and devices. By creating integrated infrastructure and simplifying approvals, the state aims to position itself as a key hub for pharma manufacturing in India.

Stay tuned for more such updates on Digital Health News